Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

loginname Oct. 28 at 4:28 AM

$ANIX there are many bid at 4 the price can’t easy down from 4 i am waiting for 3.8 but that never come next week, $ANIX will have Spartan capital sccurities if you want to bet just in this week, if you want to invest waiting 2-4 days after Spartan.

0 · Reply

loginname Oct. 24 at 3:33 PM

$ANIX good boy, mama has warmed you a cup of milk

2 · Reply

loginname Oct. 23 at 7:36 PM

$ANIX this fri or next week 🚀 too long sideway. it’s time!!

0 · Reply

topstockalerts Oct. 20 at 3:34 PM

Anixa Biosciences shares rose 2.2% in premarket trading Monday after the company announced it received a Chinese patent for its breast cancer vaccine technology. The National Intellectual Property Administration of China issued Patent No. ZL2020800215666, covering key aspects of Anixa’s breast cancer vaccine and extending protection into the 2040s across multiple global jurisdictions. Developed in collaboration with Cleveland Clinic, the vaccine targets human α-lactalbumin, a lactation-associated protein abnormally expressed in certain breast cancers. The approach aims to train the immune system to prevent tumor formation without harming normal tissue. “This newly issued patent further validates the novelty and potential of our breast cancer vaccine,” said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. He added that the patent strengthens the company’s ability to pursue global strategic opportunities as it advances clinical development in the U.S. $ANIX

0 · Reply

OpenOutcrier Oct. 20 at 12:27 PM

$ANIX (+9.8% pre) Anixa Biosciences (ANIX) Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology https://ooc.bz/l/81164

0 · Reply

LisaBethK Oct. 19 at 8:57 PM

$BCG Saw this posted on X earlier. Really exciting. Not planning on fomo but will be adding at reasonable levels in PM if I get the chance. Also adding $ANIX to WL for news cycle setup.

0 · Reply

TimRegan_WTR Oct. 17 at 12:00 AM

$ANIX

0 · Reply

research_WTR Oct. 16 at 5:20 PM

Read Robert Sassoon's recap from his latest podcast with Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: $ANIX) Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_10122025 $ANIX #Healthcare #Nutrigenomics #Podcast #SmallCap #Stocks #Investing #LoveBiome

0 · Reply

stockobserver51 Oct. 16 at 5:11 PM

$ANIX If the Nasdaq falls by a quarter soon, December 11 will be nothing more than a consolation prize for the stock.

0 · Reply

bobgilbert Oct. 16 at 3:50 AM

$ANIX with this vaccine this company goes ballistic. 👍

0 · Reply

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 20, 2025, 8:25 AM EDT - 7 days ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 7, 2025, 8:30 AM EDT - 20 days ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Sep 22, 2025, 8:05 AM EDT - 5 weeks ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 8, 2025, 8:00 AM EDT - 7 weeks ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 7 weeks ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 2 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 2 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 2 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 2 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 2 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 3 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 3 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 3 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 4 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 4 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 5 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 5 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 8 months ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 8 months ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 8 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 8 months ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Feb 24, 2025, 8:00 AM EST - 8 months ago

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Feb 18, 2025, 8:00 AM EST - 8 months ago

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Feb 14, 2025, 7:00 AM EST - 9 months ago

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Feb 11, 2025, 8:30 AM EST - 9 months ago

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Feb 4, 2025, 8:30 AM EST - 9 months ago

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Jan 21, 2025, 8:30 AM EST - 9 months ago

Anixa Biosciences CEO Provides Letter to Shareholders

Dec 4, 2024, 8:30 AM EST - 11 months ago

Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10

Nov 22, 2024, 8:15 AM EST - 1 year ago

Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 8:20 AM EST - 1 year ago

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Nov 8, 2024, 1:17 PM EST - 1 year ago

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 8:30 AM EST - 1 year ago

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 15, 2024, 9:00 AM EDT - 1 year ago

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

loginname Oct. 28 at 4:28 AM

0 · Reply

loginname Oct. 24 at 3:33 PM

$ANIX good boy, mama has warmed you a cup of milk

2 · Reply

loginname Oct. 23 at 7:36 PM

$ANIX this fri or next week 🚀 too long sideway. it’s time!!

0 · Reply

topstockalerts Oct. 20 at 3:34 PM

0 · Reply

OpenOutcrier Oct. 20 at 12:27 PM

$ANIX (+9.8% pre) Anixa Biosciences (ANIX) Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology https://ooc.bz/l/81164

0 · Reply

LisaBethK Oct. 19 at 8:57 PM

$BCG Saw this posted on X earlier. Really exciting. Not planning on fomo but will be adding at reasonable levels in PM if I get the chance. Also adding $ANIX to WL for news cycle setup.

0 · Reply

TimRegan_WTR Oct. 17 at 12:00 AM

$ANIX

0 · Reply

research_WTR Oct. 16 at 5:20 PM

0 · Reply

stockobserver51 Oct. 16 at 5:11 PM

$ANIX If the Nasdaq falls by a quarter soon, December 11 will be nothing more than a consolation prize for the stock.

0 · Reply

bobgilbert Oct. 16 at 3:50 AM

$ANIX with this vaccine this company goes ballistic. 👍

0 · Reply

Kher33 Oct. 15 at 11:53 PM

$ANIX https://www.kjrh.com/health/promising-breast-cancer-vaccine-could-be-available-by-2030-researchers-say?fbclid=IwZnRzaANdEzxleHRuA2FlbQIxMQABHlqhOAvCRSdsj5gVhHd9KGt4LMk3y5937LtQQRZSBSjGdbJ0UsKCrdp5AS_3_aem_-Q-M4g-J_2bamsZh5F9xyA

0 · Reply

JMAR_WTR Oct. 15 at 6:29 PM

$ANIX

0 · Reply

TimRegan_WTR Oct. 15 at 6:17 PM

$ANIX

0 · Reply

research_WTR Oct. 15 at 4:52 PM

New Episode: WTR Healthcare Happenings with Amit Kumar CEO of Anixa Biosciences (NASDAQ: $ANIX) 🔹 Discusses t-cell innovation and two groundbreaking clinical programs: 🔹 Modified CAR-T therapy designed to overcome challenges in treating solid tumors, including ovarian cancer 🔹 A breast cancer vaccine training antigen-specific t-cells to target triple-negative breast cancer — the most aggressive form 🔹 Hear insights on Anixa’s financial strength and strategy to drive these programs toward commercialization 🎧 Listen now on Apple Podcasts, Spotify, or at our website! Apple: https://podcasts.apple.com/us/podcast/ceo-dr-amit-kumar-discusses-anixa-biosciences-innovative/id1795488592?i=1000731955891 Spotify: https://open.spotify.com/episode/2hEd8syJqnZzNBMfh9vdWs?si=c3cdaf92c2374d67 Website: https://www.watertowerresearch.com/media-detail/2652/Media Others: https://pod.link/1795488592 #AnixaBiosciences $ANIX #Biotech #CancerResearch #CAR_T #Immunotherapy #BreastCancer #OvarianCancer #HealthcareInvesting #SmallCapStocks #WaterTowerResearch

0 · Reply

ChessHere Oct. 15 at 1:08 PM

$ANIX $ANIX wow! a lot of movement on p1 trial finished - no new news, no new data, no new insider buying… in other words there is nothing to justify the sp increase other than emotional reaction spurred by wanting Anixa to be successful ( me included). But expect the sp to go back to low 3’s until we get close to data release in Dec.. Just like every Oct. for the past three years.

0 · Reply

ChessHere Oct. 15 at 1:02 PM

$ANIX

0 · Reply

justiceforb_85 Oct. 10 at 7:53 PM

$ANIX long here and adding. Data in December will tell whether targeting alpha-lactalbumin translates from pre-clinical work in mice to humans. Would be a stunning breakthrough.

0 · Reply

Searchingforthecure Oct. 10 at 6:01 PM

$ANIX Amit should make the largest buy of his tenure. Followed by every board member and employee. That would be a huge sign of good results to come. They also need a huge partnership. I hope they can announce a $100M+ commercial partnership rather than do any dilution. Or he could sell one of the technologies and that would be a major win and allow them to do more early stage work!

0 · Reply

Rideabull Oct. 10 at 4:59 PM

$ANIX Typical slow Friday before a holiday..will pick up next week.

0 · Reply

Drugtrade Oct. 10 at 3:30 PM

$ANIX im long here.. added

0 · Reply

TDMF123 Oct. 10 at 2:07 PM

$ANIX Position Taken

0 · Reply

bioinvestorrr Oct. 10 at 12:37 PM

$ANIX at this rate idk when she will slow down, huge anticipation for december seems like everyone wants in

1 · Reply

Market Cap	136.28M
Revenue (ttm)	0.00
Net Income (ttm)	-12.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	191,900
Avg Vol	186,160
Day's Range	N/A - N/A
Shares Out	32.92M
Stochastic %K	53%
Beta	0.69
Analysts	Strong Sell
Price Target	$9.00